Drug Profile

Avacopan - ChemoCentryx/Vifor Fresenius Medical Care Renal Pharma

Alternative Names: AMG-569; CCX 168; TAVNEOS; Tavneos; Vynpenta

Latest Information Update: 16 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ChemoCentryx
Developer Amgen; ChemoCentryx; Kissei Pharmaceutical; Medpace; Vifor Fresenius Medical Care Renal Pharma
Class Amides; Anti-inflammatories; Cyclopentanes; Fluorinated hydrocarbons; Piperidines; Skin disorder therapies; Small molecules; Urologics
Mechanism of Action Complement C5a receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Granulomatosis with polyangiitis; Microscopic polyangiitis; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Membranoproliferative glomerulonephritis; Haemolytic uraemic syndrome
New Molecular Entity Yes
Available For Licensing Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis

Marketed Anti-neutrophil cytoplasmic antibody-associated vasculitis
Phase III Membranoproliferative glomerulonephritis
Phase II Haemolytic uraemic syndrome; Hidradenitis suppurativa; IgA nephropathy
No development reported Liver disorders

30 Jan 2026 The Committee for Medicinal Products for Human Use (CHMP) of EMA starts a review of Avacopan (Tavneos^®), following new information emerged raising concerns about the integrity of the data from the phase III ADVOCATE trial, which served as the primary basis for the medicine’s marketing authorisation in the EU
14 Nov 2024 Pharmacodynamic data from a phase III trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis presented at the ACR Convergence 2024 (ACR-2024)
05 Oct 2024 Amgen completes a phase I pharmacokinetics trial in healthy subjects and renal failure in USA (PO) (NCT06468826)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com